RxDoctor Payments Data

John Armbruster

Family · Bloomfield, MONPI 1003207242

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 76.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $1,980 and has fallen 78.1% since, to $433 in 2024. Among family clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,086in general payments, 2019–2025

Across 234 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • GSK$278
  • Amgen$239
  • AstraZeneca$200
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$191
  • Otsuka America Pharmaceutical, Inc.$112
  • plus $167 from 4 others

What the payments were for

  • Food & beverage$5,086100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,086 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri →

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$12,412
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,554
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,047
JardianceEmpagliflozin30$5,982
Rosuvastatin Calcium625$5,632
XareltoRivaroxaban30$5,155
VascepaIcosapent Ethyl31$3,923
TradjentaLinagliptin27$3,571
Valsartan234$3,401
Gabapentin287$3,091
Pantoprazole Sodium270$2,654
Levocetirizine Dihydrochloride299$2,497
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,045
Levothyroxine Sodium309$1,959
Fluticasone Propionate68$1,856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$30$9,55357 claims
AstraZenecaBreztri Aerosphere$200$8,55411 claims
GSKTrelegy Ellipta$278$8,04712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.

Other family in Bloomfield

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →